# Weight Loss Surgeries Decline as GLP-1 Use Skyrockets. Why This Matters
Bariatric surgery referrals have dropped sharply across the United States as glucagon-like peptide-1 (GLP-1) medications like semaglutide and tirzepatide gain popularity for weight management. This shift represents a fundamental change in how doctors and patients approach obesity treatment.
The decline in surgical procedures reflects growing confidence in pharmaceutical options. GLP-1 drugs work by slowing digestion and increasing feelings of fullness, helping people lose 15 to 22 percent of their body weight in clinical trials. Unlike weight loss surgery, which requires anesthesia and recovery time, these medications offer a less invasive path to significant weight reduction.
However, the trade-offs matter. Bariatric surgeries like gastric bypass and sleeve gastrectomy produce permanent anatomical changes and historically deliver weight loss of 50 to 70 percent. GLP-1 drugs require ongoing use. People who stop taking them typically regain weight within months.
Cost and access present real obstacles. GLP-1 medications run $900 to $1,300 monthly without insurance, while many commercial plans now cover them for eligible patients. Bariatric surgery costs $15,000 to $35,000 but often requires only one procedure. Insurance coverage for both options varies widely.
Dr. Fatima Cody Stanford, an obesity medicine specialist at Harvard Medical School, emphasizes that both approaches have roles depending on individual circumstances. People with severe obesity, multiple weight-related health conditions, or previous GLP-1 treatment failures may still benefit from surgery. Those seeking initial medical management or unable to tolerate surgery often thrive on medications.
The pharmaceutical shift raises workforce concerns. Surgeons trained in bariatric procedures face